MX2019000231A - Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas. - Google Patents

Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas.

Info

Publication number
MX2019000231A
MX2019000231A MX2019000231A MX2019000231A MX2019000231A MX 2019000231 A MX2019000231 A MX 2019000231A MX 2019000231 A MX2019000231 A MX 2019000231A MX 2019000231 A MX2019000231 A MX 2019000231A MX 2019000231 A MX2019000231 A MX 2019000231A
Authority
MX
Mexico
Prior art keywords
pyrrolo
dihydro
neurodegenerative diseases
pyridine derivatives
treating neurological
Prior art date
Application number
MX2019000231A
Other languages
English (en)
Inventor
Frank Brown Matthew
Matthew Gilbert Adam
Zhang Lei
Aaron Brodney Michael
Mary Beck Elizabeth
Ryan Butler Christopher
Ann Mcallister Laura
Alphie Lachapelle Erick
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019000231A publication Critical patent/MX2019000231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención proporciona, en parte, compuestos de Fórmula I (ver formula) O un N-óxido del mismo, o una sal farmacéuticamente aceptable del compuesto o del N-óxido, en donde R1, R2, L, A y E son como se describen en la presente descripción; procesos para la preparación de; intermedios utilizados den la preparación de; y composiciones que contienen tales compuestos, N-óxido, o sales, y sus usos para tratar trastornos mediados por M4 (o relacionados con M4) que incluyen, por ejemplo, enfermedad de Alzheimer, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), dolor, adicción y un trastorno del sueño.
MX2019000231A 2016-07-01 2017-06-15 Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas. MX2019000231A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357624P 2016-07-01 2016-07-01
US201662372421P 2016-08-09 2016-08-09
PCT/IB2017/053565 WO2018002760A1 (en) 2016-07-01 2017-06-15 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases

Publications (1)

Publication Number Publication Date
MX2019000231A true MX2019000231A (es) 2019-08-29

Family

ID=59215839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000231A MX2019000231A (es) 2016-07-01 2017-06-15 Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas.

Country Status (21)

Country Link
US (4) US10604519B2 (es)
EP (2) EP3478679B1 (es)
JP (1) JP7046018B2 (es)
KR (1) KR102470497B1 (es)
CN (1) CN109641898B (es)
AU (1) AU2017286868B2 (es)
BR (1) BR112018077257A2 (es)
CA (1) CA2972070A1 (es)
DK (1) DK3478679T3 (es)
ES (1) ES2878160T3 (es)
HU (1) HUE054857T2 (es)
IL (1) IL263912B (es)
MX (1) MX2019000231A (es)
PH (1) PH12019500004A1 (es)
PL (1) PL3478679T3 (es)
PT (1) PT3478679T (es)
SG (1) SG11201811712QA (es)
TW (1) TWI736642B (es)
UY (1) UY37311A (es)
WO (1) WO2018002760A1 (es)
ZA (1) ZA201900519B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634408B1 (en) 2017-06-09 2022-12-28 Merck Sharp & Dohme LLC Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
ES2937236T3 (es) 2017-06-22 2023-03-27 Pfizer Derivados de dihidro-pirrolo-piridina
EP4061813A1 (en) 2019-11-22 2022-09-28 F. Hoffmann-La Roche AG Pyrrolidine derivatives
CN112174869B (zh) * 2020-10-12 2023-04-25 蔡霈 N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途
WO2022235514A1 (en) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
WO2024061253A1 (zh) * 2022-09-23 2024-03-28 苏州科睿思制药有限公司 Emraclidine的晶型及其制备方法和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE60106394T3 (de) 2000-02-24 2013-07-25 Washington University St. Louis Humanisierte antikörper, die amyloid beta peptid sequestrieren
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
EP1335738A4 (en) 2000-11-03 2004-09-08 Proteotech Inc METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
KR20050071564A (ko) 2002-10-09 2005-07-07 리나트 뉴로사이언스 코퍼레이션 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (pt) 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
NZ552480A (en) 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
ATE478876T1 (de) 2004-10-25 2010-09-15 Lilly Co Eli Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PL1881985T3 (pl) 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
SI2013208T1 (sl) 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CN1869036A (zh) * 2006-06-30 2006-11-29 中国药科大学 7－取代－3－氯吡咯并[3,4－b]吡啶化合物
WO2008090429A1 (en) 2007-01-22 2008-07-31 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
EP2624697B1 (en) 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
CN103313968A (zh) * 2010-11-15 2013-09-18 Abbvie公司 Nampt和rock抑制剂
CA2831334A1 (en) * 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
EP2817295B1 (en) 2012-02-23 2017-11-01 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US11497586B2 (en) 2014-03-21 2022-11-15 Align Technology, Inc. Segmented orthodontic appliance with elastics
EP3406609A1 (en) 2014-02-06 2018-11-28 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic receptor agonists

Also Published As

Publication number Publication date
AU2017286868A1 (en) 2019-02-21
TW201811780A (zh) 2018-04-01
CA2972070A1 (en) 2018-01-01
US20210309659A1 (en) 2021-10-07
PT3478679T (pt) 2021-06-30
US20230192690A1 (en) 2023-06-22
SG11201811712QA (en) 2019-01-30
IL263912B (en) 2022-04-01
EP3478679B1 (en) 2021-04-21
KR102470497B1 (ko) 2022-11-23
HUE054857T2 (hu) 2021-10-28
US20180002331A1 (en) 2018-01-04
JP7046018B2 (ja) 2022-04-01
CN109641898A (zh) 2019-04-16
ZA201900519B (en) 2022-07-27
PL3478679T3 (pl) 2021-10-25
TWI736642B (zh) 2021-08-21
KR20190035713A (ko) 2019-04-03
ES2878160T3 (es) 2021-11-18
US20200207762A1 (en) 2020-07-02
EP3478679A1 (en) 2019-05-08
UY37311A (es) 2018-01-31
BR112018077257A2 (pt) 2019-04-02
US10604519B2 (en) 2020-03-31
WO2018002760A1 (en) 2018-01-04
PH12019500004A1 (en) 2019-10-21
US11905284B2 (en) 2024-02-20
AU2017286868B2 (en) 2021-11-11
JP2019519583A (ja) 2019-07-11
DK3478679T3 (da) 2021-06-21
EP3872078A1 (en) 2021-09-01
CN109641898B (zh) 2022-04-08
IL263912A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12018500940A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2019008690A (es) Compuestos espiro heterociclicos como inhibidores de magl.
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
TN2015000018A1 (en) 5-ht3 receptor antagonists
MX2018008653A (es) Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
MX2017003470A (es) Inhibidores macrociclicos de cinasa lrrk2.
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12019500198A1 (en) Compounds and compositions and uses thereof
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
WO2016051306A3 (en) Novel anthranilic acid derivatives
JO3483B1 (ar) 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
IN2014DN09826A (es)
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
EA201990188A1 (ru) Производные 5,7-дигидропирролопиридина
NO20084819L (no) Substituerte pyrazinonderivater for anvendelse som en medisin